Psychometric Properties and Characteristics of the North‐East Visual Hallucinations Interview in Parkinson's Disease

Holiday, Kelsey; Pirogovsky‐Turk, Eva; Malcarne, Vanessa L.; Filoteo, J. Vincent; Litvan, Irene; Lessig, Stephanie; Song, David S.; Schiehser, Dawn M.

doi:10.1002/mdc3.12479

Cited by 13 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MDS Unified Parkinson's Disease Rating Scale -Motor Examination (UPDRS-III), 6 Epworth Sleepiness Scale 7 and Geriatric Depression Scale 8 were administered to patients. The Instrumental Activities of Daily Living (IADL) scale, 9 North-East Visual Hallucinations Inventory, 10 Neuropsychiatric Inventory, 11 Mayo Sleep Questionnaire, 12 Clinician Assessment of Fluctuation 13 and Dementia Cognitive Fluctuation Scale 14 were administered to spouses or close family members acting as informants. The Clinical Dementia Rating scale (CDR) 15 was completed using clinical history and research assessments.…”

Section: Patient Recruitmentmentioning

confidence: 99%

Accuracy of dopaminergic imaging as a biomarker for mild cognitive impairment with Lewy bodies

et al. 2020

View full text Add to dashboard Cite

Background Dopaminergic imaging is an established biomarker for dementia with Lewy bodies, but its diagnostic accuracy at the mild cognitive impairment (MCI) stage remains uncertain. Aims To provide robust prospective evidence of the diagnostic accuracy of dopaminergic imaging at the MCI stage to either support or refute its inclusion as a biomarker for the diagnosis of MCI with Lewy bodies. Method We conducted a prospective diagnostic accuracy study of baseline dopaminergic imaging with [123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single-photon emission computerised tomography (123I-FP-CIT SPECT) in 144 patients with MCI. Images were rated as normal or abnormal by a panel of experts with access to striatal binding ratio results. Follow-up consensus diagnosis based on the presence of core features of Lewy body disease was used as the reference standard. Results At latest assessment (mean 2 years) 61 patients had probable MCI with Lewy bodies, 26 possible MCI with Lewy bodies and 57 MCI due to Alzheimer's disease. The sensitivity of baseline FP-CIT visual rating for probable MCI with Lewy bodies was 66% (95% CI 52–77%), specificity 88% (76–95%) and accuracy 76% (68–84%), with positive likelihood ratio 5.3. Conclusions It is over five times as likely for an abnormal scan to be found in probable MCI with Lewy bodies than MCI due to Alzheimer's disease. Dopaminergic imaging appears to be useful at the MCI stage in cases where Lewy body disease is suspected clinically.

show abstract

Section: Patient Recruitmentmentioning

confidence: 99%

Accuracy of dopaminergic imaging as a biomarker for mild cognitive impairment with Lewy bodies

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Further, this scale has both informant and patient versions which might allow for enhanced accuracy in terms of frequency. The NEVHI has shown to be a valid and reliable scale with a strong correlation with the MDS-UPDRS hallucination item score, making it a promising scale for trials focusing on VH [ 148 , 149 ] (Additional file 3 : Table S3).…”

Section: Methodsmentioning

confidence: 99%

Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations

Rodríguez‐Porcel

Wyman‐Chick

Ruiz

et al. 2022

Transl Neurodegener

View full text Add to dashboard Cite

The selection of appropriate outcome measures is fundamental to the design of any successful clinical trial. Although dementia with Lewy bodies (DLB) is one of the most common neurodegenerative conditions, assessment of therapeutic benefit in clinical trials often relies on tools developed for other conditions, such as Alzheimer’s or Parkinson’s disease. These may not be sufficiently valid or sensitive to treatment changes in DLB, decreasing their utility. In this review, we discuss the limitations and strengths of selected available tools used to measure DLB-associated outcomes in clinical trials and highlight the potential roles for more specific objective measures. We emphasize that the existing outcome measures require validation in the DLB population and that DLB-specific outcomes need to be developed. Finally, we highlight how the selection of outcome measures may vary between symptomatic and disease-modifying therapy trials.

show abstract

“…However, further analyses showed that patients in the NEVHI+ had longer non-decision times than NEVHI− and non-decision time correlated positively with higher NEVHI score in this group. As a positive NEVHI score does not necessarily reflect the incidence of visual hallucinations but can be due to other visual problems [ 43 ], we also classified patients on the basis of clinical ratings into those with a history of visual hallucinations and those without. This comparison revealed that individuals with visual hallucinations showed wider boundary separation than those without.…”

Section: Discussionmentioning

confidence: 99%

Visuo-Perceptual and Decision-Making Contributions to Visual Hallucinations in Mild Cognitive Impairment in Lewy Body Disease: Insights from a Drift Diffusion Analysis

et al. 2020

View full text Add to dashboard Cite

Background: Visual hallucinations (VH) are a common symptom in dementia with Lewy bodies (DLB); however, their cognitive underpinnings remain unclear. Hallucinations have been related to cognitive slowing in DLB and may arise due to impaired sensory input, dysregulation in top-down influences over perception, or an imbalance between the two, resulting in false visual inferences. Methods: Here we employed a drift diffusion model yielding estimates of perceptual encoding time, decision threshold, and drift rate of evidence accumulation to (i) investigate the nature of DLB-related slowing of responses and (ii) their relationship to visuospatial performance and visual hallucinations. The EZ drift diffusion model was fitted to mean reaction time (RT), accuracy and RT variance from two-choice reaction time (CRT) tasks and data were compared between groups of mild cognitive impairment (MCI-LB) LB patients (n = 49) and healthy older adults (n = 25). Results: No difference was detected in drift rate between patients and controls, but MCI-LB patients showed slower non-decision times and boundary separation values than control participants. Furthermore, non-decision time was negatively correlated with visuospatial performance in MCI-LB, and score on visual hallucinations inventory. However, only boundary separation was related to clinical incidence of visual hallucinations. Conclusions: These results suggest that a primary impairment in perceptual encoding may contribute to the visuospatial performance, however a more cautious response strategy may be related to visual hallucinations in Lewy body disease. Interestingly, MCI-LB patients showed no impairment in information processing ability, suggesting that, when perceptual encoding was successful, patients were able to normally process information, potentially explaining the variability of hallucination incidence.

show abstract

Psychometric Properties and Characteristics of the North‐East Visual Hallucinations Interview in Parkinson's Disease

Cited by 13 publications

References 39 publications

Accuracy of dopaminergic imaging as a biomarker for mild cognitive impairment with Lewy bodies

Accuracy of dopaminergic imaging as a biomarker for mild cognitive impairment with Lewy bodies

Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations

Visuo-Perceptual and Decision-Making Contributions to Visual Hallucinations in Mild Cognitive Impairment in Lewy Body Disease: Insights from a Drift Diffusion Analysis

Contact Info

Product

Resources

About